What caused Roche's Hunt­ing­ton's drug tomin­ersen to hit the skids in late-stage test? It's com­pli­cat­ed, an­a­lysts say

Just last month, Roche hit the pause but­ton on a Phase III test for Hunt­ing­ton’s hope­ful tomin­ersen af­ter a da­ta com­mit­tee ques­tioned its risk/ben­e­fit pro­file …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER